Leveraging expertise developed from his extensive work with HIV, Jackson Laboratory (JAX) Professor Derya Unutmaz, M.D., led an effort to develop an assay that determines how well anti-SARS-CoV-2 antibodies are able to neutralize binding with ACE-2, the human receptor for the virus. Using a non-infectious pseudo-virus with the SARS-CoV-2 spike protein on the external membrane, the assay does not require a BSL-3-level biosecurity facility, yet detects the presence of neutralizing antibodies with extremely high sensitivity and specificity. In a pre-print posted on medRxiv, Unutmaz shows that the assay is able to detect neutralizing antibody in patient plasma even at high dilutions, up to a million-fold. Read more |
Related Posts
Business Leaders: Deborah Bronk steers Bigelow Lab expansion to boost reach, programming
Deborah Bronk is president, CEO and a senior research scientist at Bigelow Laboratory for Ocean Sciences in East Boothbay, which will...
UNE retains R2 Research status, reinforcing leadership in scientific advancement
The University of New England has retained its status as one of the country’s leading research universities with the recent release...
Maine college students investigate health effects of forever chemicals
Two dozen Maine college students are investigating the public health effects of forever chemicals by using zebrafish as human stand-ins and...